T1	Participants 130 149	in healthy subjects
T2	Participants 538 580	to patients with hemophilia and inhibitors
T3	Participants 840 863	of N7-GP in healthy men
T4	Participants 865 998	METHODS A randomized, placebo-controlled, dose-escalation trial with five cohorts (N7-GP dose of 12.5-100 Î¼g kg(-1) ) was performed.
T5	Participants 999 1045	In each cohort, eight subjects were randomized
T6	Participants 1824 1866	in patients with hemophilia and inhibitors
